Abstract: The present application provides a compound dry powder inhalant, comprising baicalin, ambroxol hydrochloride, L-leucine and phosphate, wherein based on a mass of the compound dry powder inhalant, L-leucine accounts for 0-50%, phosphate accounts for 15-35%, and a total mass of baicalin and ambroxol hydrochloride accounts for 15-85%, and wherein a mass ratio of baicalin to ambroxol hydrochloride is 1:0.2 to 2. The compound dry powder inhalant has a Dv90?5 ?m. The drug combination of baicalin and ambroxol hydrochloride can effectively reduce inflammation and oxidative damage in lung tissue, alleviate pulmonary edema and histopathological changes, and reduce pulmonary dysfunction and pulmonary fibrosis.

Abstract: A preparation method of nitrogen-phosphorus doped porous carbon for oxygen reduction electrocatalysis within a wide pH range, which uses natural mineral-based carbon sources as raw material and uses a sequential nitrogen and phosphorus doping process for synthesizing in two paths. The method provided may be highly cost-effective, sustainable, and suitable for large-scale utilization.

Abstract: The disclosed invention relates to a low-dose celecoxib oral formulation, and a preparation method therefor, which is characterized in that the strength of the formulation is 60-90% of the original strength of the commercial celecoxib product, and the celecoxib formulation with such reduced strength is bioequivalent to the commercial celecoxib product. The celecoxib formulation can be used for the treatment of mild to moderate pain and mild to moderate chronic pain.